Medical News

Filed under: Drug, Chemotherapy, Lung Cancer, Clinical Trials, Research

A report published in the Journal of the National Cancer Institute has stated that cisplatin has better response rates than carboplatin in the treatment of advanced non-small cell lung cancer.

The two main types of lung cancer, accounting for over 90 percent of all lung cancers, are non-small cell and small cell cancer. Non-small cell lung cancer (NSCLC) accounts for most of that 90 percent.

Advanced NSCLC means that the patient’s cancer has spread to other organs or areas of the body. There has been research done to evaluate which drug is better for NSCLC — cisplatin or carboplatin. Nine clinical trials were analyzed to see what regime is a better treatment option.

The study concluded that 30 percent of patients treated with cisplatin experienced a partial or complete disappearance of detectable cancer, compared with 24 percent for those treated with carboplatin. Both of these treatments have their own unique side effects. Cisplatin resulted in more severe nausea and vomiting plus kidney problems. Carboplatin resulted in a higher risk of low platelet levels.

These results suggest that cisplatin produces slightly better response rates than carboplatin and may also improve survival in some patients.

Read | Permalink | Email this | Linking Blogs | Comments

Original post by Kristina Collins

Filed under: Drug, Chemotherapy, Lung Cancer, Clinical Trials, Research

A report published in the Journal of the National Cancer Institute has stated that cisplatin has better response rates than carboplatin in the treatment of advanced non-small cell lung cancer.

The two main types of lung cancer, accounting for over 90 percent of all lung cancers, are non-small cell and small cell cancer. Non-small cell lung cancer (NSCLC) accounts for most of that 90 percent.

Advanced NSCLC means that the patient’s cancer has spread to other organs or areas of the body. There has been research done to evaluate which drug is better for NSCLC — cisplatin or carboplatin. Nine clinical trials were analyzed to see what regime is a better treatment option.

The study concluded that 30 percent of patients treated with cisplatin experienced a partial or complete disappearance of detectable cancer, compared with 24 percent for those treated with carboplatin. Both of these treatments have their own unique side effects. Cisplatin resulted in more severe nausea and vomiting plus kidney problems. Carboplatin resulted in a higher risk of low platelet levels.

These results suggest that cisplatin produces slightly better response rates than carboplatin and may also improve survival in some patients.

Read | Permalink | Email this | Linking Blogs | Comments

Original post by Kristina Collins